Russell Investments Group
LXRX icon

Russell Investments Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Russell Investments Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.8K Buy
+19,902
New +$38.8K ﹤0.01% 3637
2024
Q4 		– Sell
-49,100
Closed -$77.1K – 3756
2024
Q3 		$77.1K Sell
49,100
-3,980
-7% -$7.09K ﹤0.01% 2708
2024
Q2 		$89.2K Buy
53,080
+3,980
+8% +$7.14K ﹤0.01% 2648
2024
Q1 		$118K Hold
49,100
– – ﹤0.01% 2548
2023
Q4 		$75.1K Hold
49,100
– – ﹤0.01% 2597
2023
Q3 		$53.5K Sell
49,100
-6,227
-11% -$10.9K ﹤0.01% 2743
2023
Q2 		$127K Hold
55,327
– – ﹤0.01% 2560
2023
Q1 		$134K Sell
55,327
-193,087
-78% -$442K ﹤0.01% 2546
2022
Q4 		$474K Hold
248,414
– – ﹤0.01% 2308
2022
Q3 		$595K Sell
248,414
-1,903
-0.8% -$5.27K ﹤0.01% 2175
2022
Q2 		$465K Hold
250,317
– – ﹤0.01% 2292
2022
Q1 		$522K Hold
250,317
– – ﹤0.01% 2212
2021
Q4 		$985K Buy
250,317
+8,130
+3% +$39.5K ﹤0.01% 2151
2021
Q3 		$1.16M Hold
242,187
– – ﹤0.01% 2122
2021
Q2 		$1.11M Hold
242,187
– – ﹤0.01% 2261
2021
Q1 		$1.42M Buy
242,187
+49,100
+25% +$340K ﹤0.01% 2077
2020
Q4 		$660K Sell
193,087
-301,443
-61% -$575K ﹤0.01% 2310
2020
Q3 		$712K Buy
494,530
+491,627
+16,935% +$875K ﹤0.01% 2225
2020
Q2 		$5K Sell
2,903
-8,612
-75% -$16.9K ﹤0.01% 3093
2020
Q1 		$22K Buy
+11,515
New +$34.3K ﹤0.01% 2945
2019
Q4 		– Sell
-67,400
Closed -$202K – 3110
2019
Q3 		$202K Buy
+67,400
New +$209K ﹤0.01% 2605
2019
Q2 		– Sell
-9,800
Closed -$55K – 2915
2019
Q1 		$55K Sell
9,800
-7,900
-45% -$48K ﹤0.01% 2795
2018
Q4 		$117K Buy
+17,700
New +$143K ﹤0.01% 2703
2017
Q4 		– Sell
-67,298
Closed -$827K – 2985
2017
Q3 		$827K Sell
67,298
-4,479
-6% -$66.1K ﹤0.01% 2232
2017
Q2 		$1.18M Sell
71,777
-367
-0.5% -$5.68K ﹤0.01% 2023
2017
Q1 		$1.03M Sell
72,144
-17,653
-20% -$262K ﹤0.01% 2080
2016
Q4 		$1.24M Buy
+89,797
New +$1.44M ﹤0.01% 2068

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Russell Investments Group's LXRX Position: Q2 2026 in Review

Russell Investments Group opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 19,902 shares worth $47.8K. The stake represents ﹤0.01% of the portfolio and ranks #3637 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in LXRX as recently as Q3 2024.

Russell Investments Group first reported a position in LXRX in Q4 2016 and has held it in 27 quarters since. The position peaked at $1.42M in Q1 2021. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Russell Investments Group held 19,902 shares of Lexicon Pharmaceuticals worth $47.8K as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Russell Investments Group position in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3637 holding.
  • Russell Investments Group first reported a position in Lexicon Pharmaceuticals in Q4 2016 and has held it in 27 quarters since.
  • Russell Investments Group's Lexicon Pharmaceuticals position peaked at $1.42M in Q1 2021.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.